#Vanqua
LightNews LightNews
wiavi.bsky.social
(Reposting some of old arts)

#kingdomhearts #rokunami #Haylette #Vanqua
October 21, 2024 at 12:29 AM
endpts.com
Biogen is paying $70M upfront to Vanqua Bio for a preclinical oral C5aR1 drug — revisiting the same target it dropped after last year’s HI-Bio buyout.
endpoints.news/biogen-pays-...
Biogen pays $70M upfront for preclinical drug with same target from HI-Bio acquisition
Biogen pays Vanqua Bio $70M upfront for global rights to preclinical C5aR1 antagonist VQ-201, with potential $990M in milestones, after dropping previous C5aR1 antibody izastobart.
endpoints.news
October 24, 2025 at 9:39 PM
milfudanshi.bsky.social
this one still a fav #vanqua #kingdomhearts
October 18, 2024 at 1:23 AM
hitaisaka.bsky.social
Falei de Vanqua mas esqueci de Soriku e Akuroku
September 14, 2024 at 1:20 PM
giger1964.bsky.social
www.vanquabio.com/vanqua-bio-t...
Looking for this #C5aR1 data. If you attended, could you please share ?
#VanquaBio #InflaRx $IFRX #Biogen $BIIB
Vanqua Bio to Present Pre-Clinical Data on VQ-201, a Next Generation C5aR1 Antagonist for the Treatment of Inflammatory Disorders - Vanqua Bio
CHICAGO, Dec. 05, 2024 (GLOBE NEWSWIRE) — Vanqua Bio, a clinical-stage biopharmaceutical company, announced that the company will present at the 8th Annual Complement-Based Drug Development Summit, wh...
www.vanquabio.com
October 28, 2025 at 6:37 PM
hitaisaka.bsky.social
E daí vem outro esquisito
Que é vanqua
September 14, 2024 at 12:44 AM
longtail-news.bsky.social
Feed: "Endpoints News"
By: Kyle LaHucik on Friday, October 24, 2025
Biogen pays $70M upfront to Vanqua Bio for immunology drug
Biogen pays Vanqua Bio $70M upfront for global rights to preclinical C5aR1 antagonist VQ-201, with potential $990M in milestones, after dropping previous C5aR1 antibody izastobart.
endpoints.news
October 25, 2025 at 2:09 AM
scientificbindery.bsky.social
Michael S. Rosen led a panel of local scientists who research diagnoses and treatments for Alzheimer's and Parkinson's: Beth Stutzman and Vidya D J from RFU, Ole Graff from Abbvie, Jim Sullivan from Vanqua Bio and Semyon Shulman from FHCC and RFU.
April 17, 2025 at 9:48 PM
blueresearch.bsky.social
Biogen licenses oral C5aR1 antagonist from Vanqua Bio
Reported Friday, Oct 24 - 7:32am EDT (TheFly subscription required to read more.)
thefly.com
October 24, 2025 at 11:40 AM
biobonanos.bsky.social
Biogen is in-licensing Vanqua's C5aR1 program for $70m up front, plus $990m in potential milestones. It's an oral small molecule that complements a mAb in BIIB's pipeline, obtained via its HI-Bio acquisition. Two shots at a pipeline-in-a-product to treat inflammatory diseases.
Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio
The oral C5aR1 antagonist is designed to modulate neutrophil-driven inflammation, a central mechanism underlying many inflammatory diseases CAMBRIDGE,...
www.globenewswire.com
October 24, 2025 at 12:10 PM
stocktitan.net
#BIIB Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio

https://www.stocktitan.net/news/BIIB/biogen-licenses-oral-c5a-r1-antagonist-from-vanqua-bio-to-expand-xsuw3wou83rh.html
Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio
Biogen Inc. (Nasdaq: BIIB) and Vanqua Bio today announced a license agreement granting Biogen
www.stocktitan.net
October 24, 2025 at 11:31 AM
biotechnetworks.bsky.social
BCBN Trending: Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio https://zpr.io/KGFTstn3j8xe
October 25, 2025 at 12:47 AM
drtimos.bsky.social
Signal or noise? > Taysha may file for approval sooner than expected;
Metagenomi ends work with Affini-T >> Comment below! #strategy #competitiveintelligence #marketing #biotech #productmarketing #healthcare #pharmaceutical #pharma
Taysha may file for approval sooner than expected; Metagenomi ends work with Affini-T
Plus, news about Hansa Biopharma, OncoC4, Leyden Laboratories, Anavex, Vanqua Bio, Bolt Biotherapeutics, AbbVie, Asabys Partners and Aliath Bioventures: ? ​​Taysha may seek approval of gene therapy earlier than expected: The company
dlvr.it
October 2, 2025 at 4:16 PM
bdsvn.bsky.social
BÁN GẤP KHO XƯỞNG MẶT TIỀN & NHIỀU KHO XƯỞNG KHÁC TẠI TP.HCM

Tin cá nhân đăng 3 giờ trước 32.000.000.000 ₫ Lưu tin Tin đã lưu Cần bán nhiều Kho Xưởng các quận Thành Phố. Tân Bình. Tân phú. Bình Tân, Q12,... + kho Xưởng 520m2 giá 32 tỷ tân bình + Kho 300m² giá 15 tỷ Tân Bình. + 1000m² giá 25ty mt…
BÁN GẤP KHO XƯỞNG MẶT TIỀN & NHIỀU KHO XƯỞNG KHÁC TẠI TP.HCM
Tin cá nhân đăng 3 giờ trước 32.000.000.000 ₫ Lưu tin Tin đã lưu Cần bán nhiều Kho Xưởng các quận Thành Phố. Tân Bình. Tân phú. Bình Tân, Q12,... + kho Xưởng 520m2 giá 32 tỷ tân bình + Kho 300m² giá 15 tỷ Tân Bình. + 1000m² giá 25ty mt Hóc Môn + Kho 1100m² giá 35 tỷ nguyễn vănquá Q12…
bds.tiki.pro.vn
April 21, 2025 at 3:32 PM
fintwitter.bsky.social
BIOGEN SHARES TURN POSITIVE AFTER LICENSE AGREEMENT WITH VANQUA BIO, LAST UP 0.6% PREMARKET
October 24, 2025 at 11:37 AM